QRxPharma seeks FDA approval for MoxDuo IR
SYDNEY — Australian drug maker QRxPharma is seeking approval for a drug that combines two painkillers in one pill, the company said Monday.
QRxPharma announced that it had filed a regulatory approval application with the Food and Drug Administration for MoxDuo IR (morphine and oxycodone). The drug is designed to release both drugs into the body immediately.
“In just four years, we have successfully moved MoxDuo IR through clinical trials and [FDA new drug application] submission by demonstrating its effectiveness and safety,” QRxPharma CEO and managing director John Holaday said. “Achievement of this milestone clearly establishes the value of this dual opioid product to patients and prescribers, as well as potential partners.